Fast-tracked cross-appeals in Delaware by Alcon Research LLC and Aurion Biotech Inc. have been closed, now that Alcon has bought a majority stake in the company that’s developing a potentially groundbreaking drug to treat corneal disease.
The parties notified the Delaware Supreme Court in a March 6 letter that they were involved in settlement negotiations. Alcon, the world’s largest eye care company, announced March 26 it was buying a majority stake in Aurion to advance its cell therapy for corneal endothelial disease into Phase 3 trials during the second half of 2025. Delaware’s top court granted the voluntary dismissal of ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.